✦ LIBER ✦

DOP062 Predictors of formation of antibodies to infliximab (ATI) and secondary loss of response in IBD patients treated with infliximab

✍ Scribed by Ungar, B.; Kopylov, U.; Yavzori, M.; Fudim, E.; Picard, O.; Lahat, A.; Avidan, B.; Lang, A.; Weiss, B.; Chowers, Y.; Eliakim, R.; Ben-Horin, S.

Book ID: 122215257
Publisher: Oxford University Press
Year: 2014
Tongue: English
Weight: 87 KB
Volume: 8
Category: Article
ISSN: 1873-9946
DOI: 10.1016/S1873-9946(14)60087-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tu1173 Infliximab Trough Levels (IFX-Tl)

Tu1173 Infliximab Trough Levels (IFX-Tl) Are Higher in Patients With Inflammatory Bowel Disease (IBD)Treated With Immunosuppressives: Clinical Correlations of IFX-LT and Antibodies to Infliximab (ATI) in IBD

✍ Daperno, Marco; Lavagna, Alessandro; Fracchia, Mario; Guiotto, Cristina; Germano 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Predictors of early response to inflixim

Predictors of early response to infliximab in patients with ulcerative colitis

✍ Marc Ferrante; Séverine Vermeire; Konstantinos H. Katsanos; Maja Noman; Gert Van 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB 👁 1 views

## Background: Our objective is to report the outcome of infliximab (ifx) in ulcerative colitis (uc) patients from a single center and to identify predictors of early clinical response. ## Methods: The first 100 uc patients (45 female; median age, 37.9 years) who received ifx at a single center w

565 Novel Infliximab (IFX) and Antibody-

565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)

✍ Brian G. Feagan; Sharat Singh; Steven Lockton; Scott Hauenstein; Linda Ohrmund; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 101 KB

P356 Loss of efficacy and adverse drug r

P356 Loss of efficacy and adverse drug reactions during infliximab therapy in IBD patients are related to the appearance of anti-infliximab antibodies

✍ A. Settesoldi; M. Giannotta; M. Milla; S. Genise; A. Santini; S. Bagnoli; V. Ann 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 52 KB

P.16.14 LOSS OF EFFICACY AND ADVERSE DRU

P.16.14 LOSS OF EFFICACY AND ADVERSE DRUG REACTIONS DURING INFLIXIMAB THERAPY IN IBD PATIENTS ARE RELATED TO THE APPEARANCE OF ANTI-INFLIXIMAB ANTIBODIES

✍ A. Settesoldi; M. Giannotta; S. Genise; A. Santini; S. Bagnoli; M. Milla; V. Ann 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Impact of Antibodies to Infliximab on Cl

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

✍ Nanda, Kavinderjit S; Cheifetz, Adam S; Moss, Alan C 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 286 KB